BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 6 (June 2019)

New Complement Therapeutics in Complement-Related Diseases Nobutaka Wakamiya 1 , Katsuki Ohtani 2 , Yoshihiko Hidaka 3 , Norimitsu Inoue 3 1Department of Medicine and Physiology, Rakuno Gakuen University 2Department of Clinical Nutrition, Rakuno Gakuen University 3Department of Molecular Genetics, Wakayama Medical University Keyword: 補体 , 補体関連疾患 , 補体活性化経路 , 膜傷害性複合体 , 治療薬 , 炎症 , Complement , complement-related diseases , complement activating pathway , membrane attack complex , MAC , therapeutics , inflammation pp.555-564
Published Date 2019/6/1
  • Abstract
  • Look Inside
  • Reference


The complement was named after “a complement”, a protein molecule that supports an antibody. It was considered previously that the complement mainly participates in protecting against microbial infections. But later, as research on biological functions in complement activation advanced drastically, it was elucidated that the complement could be involved in the onset of various diseases. In 2007, eculizumab (ECZ), an anti-C5 (complement factor 5) monoclonal antibody, was approved as a drug for paroxysmal nocturnal hemoglobinuria (PNH) in the United States. In Japan, ECZ was approved for PNH and atypical hemolytic uremic syndrome (aHUS) in 2010 and 2013, respectively. The success of ECZ created an opportunity for drug companies to develop new therapeutics targeting the complement system; development of complement therapeutics is now a major venture of pharmaceutical companies worldwide. Here, I will provide an outline of the approved complement therapeutics and those that are in development and clinical trial phase currently.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻6号 (2019年6月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院